Ethyl Acetate

Ethyl Acetate

SCHEMBL1461072

CC(=O)N(C)C.CCOC(C)=O

nearest known ligand 0.74

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.74
LMNA P02545 1/20 0.74
HSD17B10 Q99714 1/20 0.74
TSHR P16473 1/20 0.46
ALOX15 P16050 1/20 0.42
MGAM O43451 1/20 0.42
GAA P10253 1/20 0.42
SI P14410 1/20 0.42
MGAM2 Q2M2H8 1/20 0.42
SOAT1 P35610 1/20 0.42
HCAR2 Q8TDS4 1/20 0.39
CA12 O43570 2/20 0.39
CA1 P00915 2/20 0.39
CA2 P00918 2/20 0.39
CA9 Q16790 2/20 0.39
TRPA1 O75762 1/20 0.39
GLO1 Q04760 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
MAPT P10636 1/20 0.36
PGR P06401 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ethyl Acetate SCHEMBL27685753 0.89 ALDH1A1 (0.82) ALDH1A1LMNAHSD17B10TSHRALOX15
Ethyl Acetate SCHEMBL2224760 0.89 ALDH1A1 (0.58) ALDH1A1LMNAHSD17B10TSHRALOX15
Ethyl Acetate SCHEMBL28111892 0.87 ALDH1A1 (0.70) ALDH1A1LMNAHSD17B10TSHRALOX15
Ethyl Acetate SCHEMBL11138572 0.86 ALDH1A1 (0.78) ALDH1A1LMNAHSD17B10TSHRALOX15
Ethyl Acetate SCHEMBL28457765 0.86 ALDH1A1 (1.00) ALDH1A1LMNAHSD17B10TSHRALOX15
Ethyl Acetate SCHEMBL28615209 0.86 ALDH1A1 (1.00) ALDH1A1LMNAHSD17B10TSHRALOX15
Ethyl Acetate SCHEMBL30152067 0.86
Ethyl Acetate SCHEMBL1331901 0.86
Ethyl Acetate SCHEMBL1331990 0.86
Ethyl Acetate SCHEMBL70316 0.86 ALDH1A1 (1.00) ALDH1A1LMNAHSD17B10TSHRALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011033307-A1 NILOTINIB DIHYDROCHLORIDE SALT GENERICS [UK] LIMITED (GB) 2011-03-24 WO claimed
US-11834388-B2 Continuous-flow preparation method of diclofenac sodium FUDAN UNIVERSITY (CN) 2023-12-05 US disclosed
US-20230192595-A1 CONTINUOUS-FLOW PREPARATION METHOD OF DICLOFENAC SODIUM FUDAN UNIVERSITY (CN) 2023-06-22 US disclosed
US-10065969-B2 Method for producing carboxylic acid anhydride, method for producing carboxylic imide, and method for manufacturing electrophotographic photosensitive member CANON KABUSHIKI KAISHA (JP) 2018-09-04 US disclosed
US-20160376285-A1 METHOD FOR PRODUCING CARBOXYLIC ACID ANHYDRIDE, METHOD FOR PRODUCING CARBOXYLIC IMIDE, AND METHOD FOR MANUFACTURING ELECTROPHOTOGRAPHIC PHOTOSENSITIVE MEMBER CANON KABUSHIKI KAISHA (JP) 2016-12-29 US disclosed
US-9260438-B2 Solid forms of tofacitinib salts APOTEX INC. (CA) 2016-02-16 US disclosed
US-20150225406-A1 SOLID FORMS OF TOFACITINIB SALTS APOTEX INC. (CA) 2015-08-13 US disclosed
US-20150175812-A1 ANTIMICROBIAL COATINGS 3M INNOVATIVE PROPERTIES CO (US) 2015-06-25 US disclosed
WO-2011033307-A1 NILOTINIB DIHYDROCHLORIDE SALT GENERICS [UK] LIMITED (GB) 2011-03-24 WO disclosed
EP-0884311-A2 Triazole Derivatives and their production Takeda Chemical Industries, Ltd. (JP) 1998-12-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10065969-B2 Method for producing carboxylic acid anhydride, method for producing carboxylic imide, and method for manufacturing electrophotographic photosensitive member CA7, CA4, CA6 ALDH1A1 121/4885LMNA 3752/4885HSD17B10 632/4885
US-20230192595-A1 CONTINUOUS-FLOW PREPARATION METHOD OF DICLOFENAC SODIUM SULT2A1, NIT2, CA2 ALDH1A1 139/4885LMNA 3103/4885HSD17B10 3193/4885
US-20160376285-A1 METHOD FOR PRODUCING CARBOXYLIC ACID ANHYDRIDE, METHOD FOR PRODUCING CARBOXYLIC IMIDE, AND METHOD FOR MANUFACTURING ELECTROPHOTOGRAPHIC PHOTOSENSITIVE MEMBER CA7, CA4, CA6 ALDH1A1 121/4885LMNA 3752/4885HSD17B10 632/4885
US-11834388-B2 Continuous-flow preparation method of diclofenac sodium SULT2A1, NIT2, CA2 ALDH1A1 131/4885LMNA 2864/4885HSD17B10 3290/4885
US-20150225406-A1 SOLID FORMS OF TOFACITINIB SALTS JAK3, JAK2, JAK1 ALDH1A1 4512/4885LMNA 3743/4885HSD17B10 3201/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.